PUBLISHER: The Business Research Company | PRODUCT CODE: 1942756
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942756
Drug and gene delivery devices are technologies designed to transport medications or genetic material into the body for targeted therapy. They enable precise delivery to specific tissues or cells, reducing side effects and improving treatment effectiveness.
The key vector categories of drug and gene delivery devices include viral and non-viral vectors. Viral gene delivery uses genetically modified viruses to transport therapeutic genes into target cells. The delivery methods include in situ and ex vivo techniques, and the routes of administration include oral, inhalation, transdermal, injectable, ocular, nasal, and topical routes.
Tariffs are impacting the drug and gene delivery devices market by increasing the cost of imported materials, components, and specialized manufacturing equipment for viral and non-viral vector production. Segments such as lipid nanoparticles, polymeric nanoparticles, and viral vectors are most impacted, particularly in regions like North America and Asia-Pacific. While tariffs have raised production costs and slowed supply chains, they have also encouraged local manufacturing, investment in domestic capabilities, and innovation in alternative materials and delivery technologies.
The drug and gene delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug and gene delivery devices market statistics, including drug and gene delivery devices industry global market size, regional shares, competitors with a drug and gene delivery devices market share, detailed drug and gene delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug and gene delivery devices industry. This drug and gene delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug and gene delivery devices market size has grown strongly in recent years. It will grow from $0.67 billion in 2025 to $0.73 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to limited availability of advanced delivery devices, reliance on conventional administration routes, early-stage gene therapy development, growing biologics pipeline, increasing investment in research collaborations.
The drug and gene delivery devices market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to technological advancements in viral and non-viral vectors, expansion of personalized medicine and gene therapy applications, increasing regulatory approvals for innovative delivery systems, rising adoption of nanomedicine and LNPs, integration of digital monitoring and smart delivery platforms. Major trends in the forecast period include growth of targeted drug and gene therapies, rising adoption of nanoparticle-based delivery systems, increasing use of viral vectors for gene therapy, expansion of injectable and non-invasive delivery methods, focus on personalized medicine and controlled release technologies.
The increasing adoption of gene therapy is anticipated to support the expansion of the drug and gene delivery devices market going forward. Gene therapy involves modifying genetic material within a patient's cells to treat or prevent disease and is gaining attention due to its potential to address genetic and chronic conditions at their underlying causes. The growing adoption of gene therapy has increased demand for advanced delivery systems capable of precise targeting and controlled release of therapeutic genes. Drug and gene delivery devices play a critical role in enhancing treatment effectiveness and safety. For example, in January 2025, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization, the number of pre-registration gene therapy programs in Q4 2024 increased by 83% compared to Q3 2024. As a result, the expanding adoption of gene therapy is reinforcing growth across the drug and gene delivery devices market.
Leading companies operating in the drug and gene delivery devices market are focusing on developing advanced solutions, such as artificial intelligence (AI)-enabled technologies, to enhance market competitiveness. AI technology in drug delivery involves the application of advanced algorithms and data-driven models to improve delivery precision, efficiency, and therapeutic effectiveness. For example, in December 2023, Envoya Inc., a US-based developer of polymer-based nanoparticles, launched an innovative gene therapy delivery platform that combines biopolymer nanoparticles with AI. This platform is designed to address limitations of existing gene delivery methods, including safety concerns, restricted payload capacity, and limited tissue targeting associated with viral vectors and lipid nanoparticles.
In January 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Poseida Therapeutics Inc. for $1.5 billion. Through this acquisition, Roche aims to strengthen its oncology pipeline and expand its capabilities in allogeneic CAR-T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. Poseida Therapeutics Inc. is a US-based company specializing in complex immune cell therapies, including genetically modified CAR-T therapies for cancer and autoimmune disorders.
Major companies operating in the drug and gene delivery devices market are Medtronic plc, Moderna Inc., Halozyme Therapeutics Inc., Uniqure NV, Intellia Therapeutics Inc., Voyager Therapeutics Inc., sfm medical devices GmbH, Inovio Pharmaceuticals Inc., GenSight Biologics S.A., CRISPR Therapeutics, Pfizer Inc., Novartis AG, Becton Dickinson and Company, Shanghai Sunway Biotech Co Ltd, Epeius Biotechnologies Corporation, SiBiono GeneTech Co Ltd, F Hoffmann-La Roche Ltd, Baxter International, B Braun Melsungen, Terumo Corporation, ICU Medical, Stevanato Group, Gerresheimer AG, Ypsomed, SHL Medical
North America was the largest region in the drug and gene delivery devices market in 2025. The regions covered in the drug and gene delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug and gene delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The drug and gene delivery devices market consists of sales of microspheres and microneedles, electroporation devices, bio adhesive systems, and gene therapy vectors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug And Gene Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug and gene delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug and gene delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug and gene delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.